tiprankstipranks
Advertisement
Advertisement

ANTX Stock Latest News

AN2 Therapeutics upgraded to Outperform from Market Perform at Leerink
The FlyAN2 Therapeutics upgraded to Outperform from Market Perform at Leerink
7d ago
ANTX
AN2 Therapeutics reports Q1 EPS (29c), one estimate (23c)
PremiumThe Fly
AN2 Therapeutics reports Q1 EPS (29c), one estimate (23c)
10d ago
ANTX
AN2 Therapeutics, Inc. (ANTX) Q1 Earnings Cheat Sheet
PremiumPre-Earnings
AN2 Therapeutics, Inc. (ANTX) Q1 Earnings Cheat Sheet
10d ago
ANTX
AN2 Therapeutics Completes First-in-Human Trial, Setting Up the Next Catalyst for ANTX
PremiumCompany Announcements
AN2 Therapeutics Completes First-in-Human Trial, Setting Up the Next Catalyst for ANTX
21d ago
ANTX
AN2 Therapeutics Launches New $80 Million ATM Program
PremiumCompany Announcements
AN2 Therapeutics Launches New $80 Million ATM Program
1M ago
8K
ANTX
AN2 Therapeutics files $300M mixed securities shelf
PremiumThe FlyAN2 Therapeutics files $300M mixed securities shelf
1M ago
ANTX
AN2 Therapeutics announces initiation of Phase 2 trial of epetraborole
Premium
The Fly
AN2 Therapeutics announces initiation of Phase 2 trial of epetraborole
2M ago
ANTX
AN2 Therapeutics Reprices Stock Options to Enhance Retention
Premium
Company Announcements
AN2 Therapeutics Reprices Stock Options to Enhance Retention
2M ago
8K
ANTX
AN2 Therapeutics reports Q4 EPS (29c) vs (25c) last year
PremiumThe Fly
AN2 Therapeutics reports Q4 EPS (29c) vs (25c) last year
2M ago
ANTX
AN2 Therapeutics Announces $40 Million Private Placement Financing
PremiumCompany Announcements
AN2 Therapeutics Announces $40 Million Private Placement Financing
2M ago
8K
ANTX
AN2 Therapeutics to advance oral Epetraborole into Phase 2 study
PremiumThe Fly
AN2 Therapeutics to advance oral Epetraborole into Phase 2 study
3M ago
ANTX
AN2 Therapeutics adjusts leadership roles and executive compensation
PremiumCompany Announcements
AN2 Therapeutics adjusts leadership roles and executive compensation
4M ago
8K
ANTX
AN2 Therapeutics announces FDA clearance of OSHU IND application
PremiumThe FlyAN2 Therapeutics announces FDA clearance of OSHU IND application
4M ago
ANTX
AN2 Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
AN2 Therapeutics Reports Q3 2025 Financial Results
6M ago
ANTX
AN2 Therapeutics reports Q3 EPS (31c), two estimates (22c)
Premium
The Fly
AN2 Therapeutics reports Q3 EPS (31c), two estimates (22c)
6M ago
ANTX
AN2 Therapeutics announces tuberculosis collaboration agreement with GSK
PremiumThe Fly
AN2 Therapeutics announces tuberculosis collaboration agreement with GSK
6M ago
GSK
ANTX
AN2 Therapeutics Advances with Phase 1 Trial of Oral AN2-502998
PremiumCompany Announcements
AN2 Therapeutics Advances with Phase 1 Trial of Oral AN2-502998
7M ago
ANTX
AN2 Therapeutics, Inc.: Hold Rating Amid Early-Stage Progress and Financial Uncertainty
PremiumRatings
AN2 Therapeutics, Inc.: Hold Rating Amid Early-Stage Progress and Financial Uncertainty
9M ago
ANTX
AN2 Therapeutics Reports Improved Financial Results
PremiumCompany Announcements
AN2 Therapeutics Reports Improved Financial Results
9M ago
ANTX
AN2 Therapeutics reports Q2 EPS (21c) vs. (48c) last year
PremiumThe FlyAN2 Therapeutics reports Q2 EPS (21c) vs. (48c) last year
9M ago
ANTX
AN2 Therapeutics completes dosing in cohort in AN2-502998 trial
Premium
The Fly
AN2 Therapeutics completes dosing in cohort in AN2-502998 trial
9M ago
ANTX
AN2 Therapeutics, DNDi collaborate on development of AN2-502998
Premium
The Fly
AN2 Therapeutics, DNDi collaborate on development of AN2-502998
10M ago
ANTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >